<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-59677</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Safety of adalimumab</dc:title>
<dc:description xml:lang="en">The safety data for adalimumab in psoriasis are similar to those described for other indications authorized for this drug. Most of the adverse effects observed (mainly, reaction at the injection point and upper respiratory tract infections) are of mild intensity and do not make it necessary to discontinue the drug. Serious adverse effects have been described in a low proportion of patients and include infections (tuberculosis and other opportunistic infections), lymphoproliferative conditions, autoimmune diseases and demyelinizing processes. Similar to other anti-tumor necrosis factor alpha (anti-TNF&amp;#945;) treatments, the experience with adalimumab only provides information regarding its middle term safety. Thus, some years are needed to verify these results in the longer term. Due to this, the patients who are candidates for the drug must be correctly screened and they must be closely monitored during the treatment period and until 5 months after it (AU)</dc:description>
<dc:creator>Ferran, M</dc:creator>
<dc:creator>Pujol, R. M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En la psoriasis, los datos de seguridad para adalimumab son similares a los descritos en las otras indicaciones autorizadas para este fármaco. La mayoría de efectos adversos objetivados (principalmente reacción en el punto de inyección e infecciones del tracto respiratorio superior) son de intensidad leve y no requieren la retirada del fármaco. Los efectos adversos graves han sido descritos en una baja proporción de pacientes e incluyen infecciones (tuberculosis y otras infecciones oportunistas), procesos linfoproliferativos, enfermedades autoinmunes y procesos desmielinizantes. De forma similar a otros tratamientos anti-factor de necrosis tumoral alfa (TNF-&amp;#945;), la experiencia con adalimumab sólo aporta información con respecto a su seguridad a medio plazo, por lo que deberán pasar unos años para poder confirmar estos resultados a más largo plazo. Por todo esto es imprescindible realizar un cribaje correcto de los pacientes candidatos al fármaco y monitorizarlos estrechamente durante el período de tratamiento y hasta 5 meses después (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;99(supl.3): 15-24, feb. 2008. ilus, tab</dc:source>
<dc:identifier>ibc-59677</dc:identifier>
<dc:title xml:lang="es">Seguridad de adalimumab</dc:title>
<dc:subject>^d24718^s22012</dc:subject>
<dc:subject>^d24718^s22057</dc:subject>
<dc:subject>^d29623</dc:subject>
<dc:subject>^d7145^s22057</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29594^s22057</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d12002^s22080</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d13552^s22057</dc:subject>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d22261</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d29490^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12002^s22016</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d3894^s22057</dc:subject>
<dc:subject>^d29431^s22066</dc:subject>
<dc:subject>^d29431^s22045</dc:subject>
<dc:subject>^d8403^s22012</dc:subject>
<dc:subject>^d28169^s22073</dc:subject>
<dc:subject>^d8403^s22057</dc:subject>
<dc:subject>^d29591^s22021</dc:subject>
<dc:subject>^d24527^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200802</dc:date>
</metadata>
</record>
</ibecs-document>
